Evaluation of Safety and Tolerability of Long-term TEV-50717 for Treatment of Tourette Syndrome

- Tourette Syndrome
- Terminated

Study Title: Evaluation of Safety and Tolerability of Long-term TEV-50717 (Deutetrabenazine) for Treatment of Tourette Syndrome in Children and Adolescents

Teva Identifier: TV50717-CNS-30047 | 2016-000630-22

ClinicalTrials.gov Identifier: NCT03567291

Study Status: Terminated

Trial Condition(s): Tourette Syndrome

Interventions: Drug: TEV-50717 | Drug: Placebo

Study Description

Please refer to ClinicalTrials.gov for a description of the trial

Participation criteria and map of study locations

Key Participation Requirements

Gender: Female, Male

Age group: Child

Age Range: 6 Years to 17 Years

Trial Duration: May 25, 2018 - May 15, 2020

Phase: Phase 3

Study Type

Interventional